Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Jan;117(1):1–4. doi: 10.1111/j.1476-5381.1996.tb15146.x

Pharmacokinetics of phenazone (antipyrine) in rabbits with experimental common bile duct obstruction.

J Wójcicki 1, T Sulikowski 1, M Wójcicki 1, M Droździk 1, B Gawrońska-Szklarz 1, B Barcew-Wiszniewska 1, J Skowron 1, L Rózewicka 1
PMCID: PMC1909376  PMID: 8825335

Abstract

1. An altered functional state of liver due to experimental cholestasis could result in a change in the biotransformation of drugs. The aim of this study was to evaluate an influence of obstructive cholestasis on the pharmacokinetics of phenazone (antipyrine). 2. The investigation was carried out on male rabbits, randomly allocated into two groups: shamoperated and animals with biliary ducts ligation. Phenazone was administered intragastrically as a probe of drug metabolism. 3. Measurements, i.e. laboratory and pharmacodynamic tests, as well as pharmacokinetic assays, were performed before the operation as well as 10-12 days after the bile duct ligation. At the end of the study livers were examined macro- and microscopically and biochemical analysis of the liver microsomes was performed. 4. The measured pharmacokinetic parameters suggested an impaired biotransformation of phenazone in animals with obstructive cholestasis, leading to a slower drug elimination.

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BARTLETT G. R. Phosphorus assay in column chromatography. J Biol Chem. 1959 Mar;234(3):466–468. [PubMed] [Google Scholar]
  2. Basseches P. J., DiGregorio G. J. Pharmacokinetics of procainamide in rats with extrahepatic biliary obstruction. J Pharm Sci. 1982 Nov;71(11):1256–1259. doi: 10.1002/jps.2600711118. [DOI] [PubMed] [Google Scholar]
  3. Bengochea L., Ouviña G., Sozzani P., Lemberg A. Protein and lipid disturbances in rat liver microsomal membranes after bile duct ligation. Biochem Biophys Res Commun. 1987 Apr 29;144(2):980–985. doi: 10.1016/s0006-291x(87)80060-8. [DOI] [PubMed] [Google Scholar]
  4. Buters J. T., Zysset T., Reichen J. Metabolism of antipyrine in vivo in two rat models of liver cirrhosis. Its relationship to intrinsic clearance in vitro and microsomal membrane lipid composition. Biochem Pharmacol. 1993 Sep 14;46(6):983–991. doi: 10.1016/0006-2952(93)90662-g. [DOI] [PubMed] [Google Scholar]
  5. Carulli N., Manenti F., Ponz de Leon M., Ferrari A., Salvioli G., Gallo M. Alteration of drug metabolism during cholestasis in man. Eur J Clin Invest. 1975 Nov 21;5(6):455–462. doi: 10.1111/j.1365-2362.1975.tb00477.x. [DOI] [PubMed] [Google Scholar]
  6. Elfström J., Lindgren S. Disappearance of phenazone from plasma in patients with obstructive jaundice. Eur J Clin Pharmacol. 1974 Oct 4;7(6):467–471. doi: 10.1007/BF00560360. [DOI] [PubMed] [Google Scholar]
  7. Fruncillo R. J., DeAngelis P., DiGregorio G. J. Pharmacokinetics of theophylline in rats with biliary stasis. J Pharm Pharmacol. 1982 Nov;34(11):741–743. doi: 10.1111/j.2042-7158.1982.tb06215.x. [DOI] [PubMed] [Google Scholar]
  8. Hepner G. W., Vesell E. S. Aminopyrine metabolism in the presence of hyperbilirubinemia due to cholestasis or hepatocellular disease. Combined use of laboratory tests to study disease-induced alterations in drug disposition. Clin Pharmacol Ther. 1977 May;21(5):620–626. doi: 10.1002/cpt1977215620. [DOI] [PubMed] [Google Scholar]
  9. Hepner G. W., Vesell E. S. Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction. Am J Dig Dis. 1975 Jan;20(1):9–12. doi: 10.1007/BF01073131. [DOI] [PubMed] [Google Scholar]
  10. Imaoka S., Imai Y., Shimada T., Funae Y. Role of phospholipids in reconstituted cytochrome P450 3A form and mechanism of their activation of catalytic activity. Biochemistry. 1992 Jul 7;31(26):6063–6069. doi: 10.1021/bi00141a015. [DOI] [PubMed] [Google Scholar]
  11. Kalow W., Tang B. K. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):508–519. doi: 10.1038/clpt.1991.176. [DOI] [PubMed] [Google Scholar]
  12. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  13. Loft S. Metronidazole and antipyrine as probes for the study of foreign compound metabolism. Pharmacol Toxicol. 1990;66 (Suppl 6):1–31. doi: 10.1111/j.1600-0773.1990.tb01611.x. [DOI] [PubMed] [Google Scholar]
  14. OMURA T., SATO R. THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES. J Biol Chem. 1964 Jul;239:2379–2385. [PubMed] [Google Scholar]
  15. Reichen J., Buters J. T., Sojcic Z., Roos F. J. Abnormal lipid composition of microsomes from cirrhotic rat liver--does it contribute to decreased microsomal function? Experientia. 1992 May 15;48(5):482–486. doi: 10.1007/BF01928168. [DOI] [PubMed] [Google Scholar]
  16. Rudel L. L., Morris M. D. Determination of cholesterol using o-phthalaldehyde. J Lipid Res. 1973 May;14(3):364–366. [PubMed] [Google Scholar]
  17. Viktorov A. P., Rybak A. T. Ispol'zovanie antipirinovogo testa pri izuchenii mikrosomal'nogo okisleniia lekarstvennykh sredstv. Farmakol Toksikol. 1990 Jan-Feb;53(1):74–77. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES